Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 377 across all filing types
Latest filing 2020-04-03 AGM Information
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Kallelse till Årsstämma i Immunovia AB
AGM Information Classification · 99% confidence The document is titled "Kallelse till Årsstämma i Immunovia AB" (Notice of Annual General Meeting in Immunovia AB) and explicitly details the date, time, location, agenda items (including election of chairman, approval of annual report, remuneration, and authorization for new share issues), and proposals for shareholder voting. This content directly corresponds to the preparatory materials sent out before an Annual General Meeting (AGM). The definition for AGM Information (AGM-R) covers 'Presentations and materials shared during the Annual General Meeting (AGM)'. While this is a notice/call, it contains the core material for the meeting itself, making AGM-R the most specific fit over a general Regulatory Filing (RNS) or a Proxy Statement (PSI), as it is the official call and proposal document for the AGM.
2020-04-03 English
Immunovia Takes Action During COVID-19 Pandemic and Remains Focused on Launch of IMMray[™] PanCan-d
Environmental & Social Information Classification · 99% confidence The document is titled "PRESS RELEASE" and provides an update on company operations, specifically regarding the COVID-19 pandemic's impact and the continued focus on the commercial launch of their product, IMMray™ PanCan-d. It details operational adjustments, progress on verification/validation studies, and concludes by announcing a live call to discuss these matters. The presence of a specific date (April 1, 2020), a summary of business updates, and the announcement of a conference call strongly suggest this is an Earnings Release (ER) or a general operational update. Since it is a press release providing key highlights and updates rather than a full, comprehensive financial report (like a 10-K or IR), 'ER' is the most appropriate classification. It is not a transcript (CT), a formal regulatory filing like 10-K, or a pure announcement of a report publication (RPA).
2020-04-01 English
Immunovia vidtar åtgärder under COVID-19-pandemin och behåller fokus på lanseringen av IMMray® PanCan-d
Regulatory Filings Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and is dated April 1, 2020. It provides an update on the company's response to the COVID-19 pandemic and maintains focus on the planned Q3 2020 launch of its diagnostic test, IMMray® PanCan-d. It details operational adjustments, progress on verification/validation studies, and announces a conference call to discuss these updates. This structure—an official announcement detailing operational status, business continuity, and upcoming milestones, often including details about an associated call—is characteristic of an Earnings Release (ER) or a general business update. Since it is not a full financial report (like 10-K or IR) but rather a summary of current events and business status, ER is the most appropriate classification. The document also explicitly mentions that the information is being released under EU Market Abuse Regulation, confirming its status as a formal regulatory disclosure, but the content is focused on operational updates rather than just a filing announcement.
2020-04-01 Swedish
Audit Report / Information 2019
Audit Report / Information Classification · 98% confidence The document is titled "2019 Årsredovisning" (2019 Annual Report) and contains a detailed "Innehållsförteckning" (Table of Contents) listing sections such as 'Förvaltningsberättelse' (Directors' Report), 'Finansiella rapporter' (Financial Reports) including 'Koncernens resultaträkning' (Group Income Statement) and 'Koncernens balansräkning' (Group Balance Sheet), and 'Revisionsberättelse' (Auditor's Report). It also includes a 'Hållbarhetsrapport' (Sustainability Report) and 'Bolagsstyrningsrapport' (Corporate Governance Report) within the same document structure. The length (286,377 characters) is substantial, indicating a comprehensive annual filing, not just a brief announcement. Although the text is in Swedish, the structure and content strongly align with a full Annual Report, which corresponds to the 10-K filing type in the US context, or a comprehensive annual report in general. FY 2019
2020-04-01 Swedish
Annual Report 2019
Annual Report Classification · 100% confidence The document is explicitly titled '2019 Annual Report' and contains comprehensive sections including a CEO statement, market overview, sustainability report, corporate governance report, statutory administration report, and full audited financial statements (consolidated and parent company). It covers the fiscal year 2019 and provides detailed business and financial performance analysis, fitting the definition of a 10-K/Annual Report. FY 2019
2020-04-01 English
Styrelseledamot Hans Johansson köper Immunovia aktier
Director's Dealing Classification · 99% confidence The document is a press release titled "Styrelseledamot Hans Johansson köper Immunovia aktier" (Board Member Hans Johansson buys Immunovia shares). It explicitly states that a director (Hans Johansson) has purchased shares for 0.5 MSEK, increasing his total holding. This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). Therefore, the appropriate filing code is DIRS.
2020-03-26 Swedish

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.